Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ZAVESCA safely and effectively. See full prescribing information for ZAVESCA. ZAVESCA ® (miglustat) capsules, for oral use Initial U.S. Approval: 2003
Medication labelWhy this: Advisory · dailymed-prescription
ZAVESCA is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).
- generic_name
- miglustat
- product_names
- miglustat
- ndc
- 66215-201, 66215-201-15, 66215-201-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en